CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$1.52 USD
-0.15 (-8.98%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $1.58 +0.06 (3.95%) 5:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CASI 1.52 -0.15(-8.98%)
Will CASI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
CASI forms Lower Bollinger Band Walk on September 22
CASI forms MACD Bearish Centerline Cross on September 19
Fell Below 50 Day Moving Average appears for CASI after 6.56% move
CASI forms Lower Bollinger Band Walk on September 17
Is CASI gathering momentum? Narrow Range Bar shows up after sliding 3.83%